Table 2.
2 L chemotherapy
| Therapy, n (%)a | Australia (N = 34) | Canada (N = 100) | Italy (N = 84) | UK (N = 62) | Overall (N = 280) |
|---|---|---|---|---|---|
| Monotherapy | 20 (58.8%) | 48 (48.0%) | 38 (45.2%) | 39 (62.9%) | 145 (51.8%) |
| Combination therapyb | 14 (41.2%) | 52 (52.0%) | 46 (54.8%) | 23 (37.1%) | 135 (48.2%) |
| Doublet chemotherapy | 10 (71.4%) | 39 (75.0%) | 38 (82.6%) | 15 (65.2%) | 102 (75.6%) |
| Triplet chemotherapy | 4 (28.6%) | 13 (25.0%) | 8 (17.4%) | 7 (30.4%) | 32 (23.7%) |
| Monotherapyc | |||||
| Taxanes | 10 (50.0%) | 23 (47.9%) | 29 (76.3%) | 38 (97.4%) | 100 (69.0%) |
| Irinotecan | 6 (30.0%) | 21 (43.8%) | 4 (10.5%) | 1 (2.6%) | 32 (22.1%) |
| Fluoropyrimidines | 2 (10.0%) | 3 (6.3%) | 1 (2.6%) | - | 6 (4.1%) |
| Ramucirumab | - | 1 (2.1%) | 3 (7.9%) | - | 4 (2.8%) |
| Platinum | 1 (5.0%) | - | 1 (2.6%) | - | 2 (1.4%) |
| Other monotherapy | 1 (5.0%) | - | - | - | 1 (0.7%) |
| Doublet chemotherapyc | |||||
| Fluoropyrimidine + irinotecan | 2 (14.3%) | 25 (48.1%) | 18 (39.1%) | - | 45 (33.3%) |
| Fluoropyrimidine + platinum | 5 (35.7%) | 6 (11.5%) | 4 (8.7%) | 9 (39.1%) | 24 (17.8%) |
| Taxanes + ramucirumab | - | 2 (3.8%) | 10 (21.7%) | 1 (4.3%) | 13 (9.6%) |
| Taxanes + trastuzumab | - | - | 3 (6.5%) | 2 (8.7%) | 5 (3.7%) |
| Other doublet | 3 (21.4%) | 6 (11.5%) | 3 (6.5%) | 3 (13.0%) | 15 (11.1%) |
| Triplet chemotherapyc | |||||
| Fluoropyrimidine + platinum + anthracycline | 4 (28.6%) | 5 (9.6%) | 3 (6.5%) | 3 (13.0%) | 15 (11.1%) |
| Fluoropyrimidine + platinum + other | - | 8 (15.4%) | 5 (10.9%) | 2 (8.7%) | 15 (11.1%) |
| Other triplet | - | - | - | 2 (8.7%) | 2 (1.5%) |
a Specific drugs used are tabulated in the supplementary material
b Percentages receiving doublet and triplet are out of number of patients who received combination therapy
c Percentages for individual regimens are out of number of patients who received monotherapy or combination therapy, respectively